Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
25 Results for "
PIK3CA
" in MedChemExpress (MCE) Product Catalog:
Products (25)
25 Results for "PIK3CA" in MCE Product Catalog:
23
23 Publications Verification
Synonyms: GDC-0032; RG-7604
Taselisib (GDC-0032) is a potent PI3K inhibitor targets PIK3CA mutations, with Kis of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.
3
Izorlisib (CH5132799) is an orally active, selective Class I PI3K inhibitor with an IC50 value of 14 nM against PI3Kα. Izorlisib specifically inhibits Class I PI3K (particularly PI3Kα and its mutants) and blocks the PI3K/Akt/mTOR pathway; this leads to cell cycle arrest at the G1 phase and apoptosis without triggering feedback activation of Akt by competitively binding to the ATP-binding site of PI3K. Izorlisib can be used in research on cancers harboring PIK3CA mutations or PTEN loss (such as breast, ovarian, prostate, and endometrial cancers) .
1
Zovegalisib (RLY-2608) is an orally active first-in-class allosteric mutant-selective inhibitor of PI3Ka with anti-tumor activity. Zovegalisib inhibits tumor growth in PIK3CA-mutant xenograft mice models with minimal impact on insulin [3].
1
Target:
Research Areas:
MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (Kd: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC50 of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer .
1
1 Cited Publications
BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth .
1
1 Cited Publications
Cat. No.: HY-P703580
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: PIK3CA; Phosphatidylinositol-4,5-Bisphosphate 3-Kinase; Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PI3-Kinase P110 Subunit Alpha; Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform; PtdIns-3-Kinase
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-137849
CAS No.: 2171388-28-4
RK-582 is a tankyrase inhibitor, antitumor agent, and orally bioavailable growth inhibitor, with an IC50 of 36.1 nM against human tankyrase-1 and an IC50 of 39.2 nM against human tankyrase-2. In APC-mutated colorectal cancer cells, the sensitivity to RK-582 correlates with the level of active β-catenin, while drug resistance associates with PIK3CA mutation. RK-582 can be used for the research of colorectal cancer .
Cat. No.: HY-RS10523
Target:
Research Areas:
PIK3CA Human Pre-designed siRNA Set A contains three designed siRNAs for PIK3CA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS10524
Target:
Research Areas:
Pik3ca Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pik3ca gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS10525
Target:
Research Areas:
Pik3ca Rat Pre-designed siRNA Set A contains three designed siRNAs for Pik3ca gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-N4259
CAS No.: 90985-77-6
Cat. No.: HY-N12726
CAS No.: 2977255-36-8
Cat. No.: HY-172964
CAS No.: 2559686-28-9
KIM-161 is a PIK3CA inhibitor. KIM-161 has significant antiproliferative activity with IC50 values of 1.428 and 1.562 µM against PI3KCA mutant breast cancer MCF7 and T47D cells, respectively. KIM-161 induces apoptosis and cell cycle arrest by inhibiting the PI3K/AKT/mTOR signaling pathway and inducing ROS production. KIM-161 can be used to study breast cancer and its PI3KCA mutant subtypes .
Cat. No.: HY-138302
CAS No.: 2067281-52-9
Target:
Research Areas:
PF-06862309 is a PF-06843195 (HY-131972) phosphate ester prodrug. PF-06862309 can be hydrolyzed to PF-06843195 in the presence of alkaline phosphatase. PF-06843195 is a highly selective PI3Kα inhibitor. PF-06862309 can be used for the study of breast cancer with ER +, HER 2-, and PIK3CA mutations .
Cat. No.: HY-116191
CAS No.: 1309087-83-9
WJD008 is a potent dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor with antiproliferative and anticlonogenic activity in tumor cells and transformed cells with PIK3CA mutant. WJD008 inhibits kinase activity of PI3K α and mTOR and abrogates insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling cascade. WJD008 is promising for research of cancers .
Cat. No.: HY-P705719
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: PIK3CA; Phosphatidylinositol-4,5-Bisphosphate 3-Kinase; Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PI3-Kinase P110 Subunit Alpha; Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform; PtdIns-3-Kinase
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-100886R
CAS No.: 1375469-38-7
Target:
Research Areas:
BAY1082439 (Standard) is the analytical standard of BAY1082439 (HY-100886). This product is intended for research and analytical applications. BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth .
Cat. No.: HY-P810808
Synonyms: PI3-kinase subunit alpha, PI3K-alpha, PI3Kalpha, PtdIns-3-kinase subunit alpha, Phosphoinositide 3-kinase alpha, Phosphoinositide-3-kinase catalytic alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit p110-alpha, p110alpha, PIK3CA
Cat. No.: HY-108232R
CAS No.: 1032349-77-1
MK-2206 (Standard) is the analytical standard of MK-2206 (HY-108232). This product is intended for research and analytical applications. MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC50s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities .
Cat. No.: HY-100424
CAS No.: 1202041-71-1
PI3K-IN-63 is a selective PI3Kα inhibitor with a Ki of 0.35 nM against human targets. PI3K-IN-63 inhibits the phosphorylation of AKT at the S473 site in cellular assays. PI3K-IN-63 reduces the viability of non-small cell lung cancer cell lines carrying PIK3CA mutations. PI3K-IN-63 can be used in studies related to non-small cell lung cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
